20 likes | 180 Vues
Researchers at the Friedman Lab, UMKC School of Pharmacy, have developed a groundbreaking light-activated insulin depot aimed at reducing the need for insulin injections and enhancing blood sugar control. This patented technology links insulin to a polymer with a light-cleavable linker, allowing the drug to be released under the skin in response to blood sugar cues via irradiation. The method has been described as a "paradigm shift" in diabetes treatment and is featured in the prestigious Angewandte Chemie. The global insulin market could be worth approximately $0.5 trillion over its patent lifetime.
E N D
Using Light to Control Drug Release Work from the Friedman Lab at the UMKC School of Pharmacy Aim: Eliminate most insulin injections, improve blood sugar control. • Drug (Insulin) linked to polymer with light cleavable linker. • Material injected under the skin, irradiated in response to blood sugar cues. www.friedmanlaboratory.org
A Light Activated Insulin Depot Described as “Truly Innovative” and “A Paradigm Shift” by reviewer. Featured on frontispiece of AngewandteChemie (~14 impact factor). Reported by AP in multiple sites. Covered by KSHB NBC affiliate. Worldwide Insulin market over lifetime of patent: ~ $0.5 trillion www.friedmanlaboratory.org